Gengnianan Tablets

Shop Now

Overview

What is Gengnianan Tablets?

Gengnianan Tablets are a proprietary Chinese herbal medicine made from 15 herbs. It is mainly used for menopausal symptoms including hot flashes or sweating, dizziness, tinnitus, insomnia, and irritability.

Product Information

Chinese name更年安片
PinyinGengnianan Pian
BrandSanghai
China Drug Approval No.Z20073293
Dosage formtablet
Traditional functionNourishes yin, clears heat, and calms vexation or the mind.
Strength0.31 g per film-coated tablet
Individual package0.31 g × 60 tablets
Recommended useLabeled for menopausal symptoms including hot flashes or sweating, dizziness, tinnitus, insomnia, and irritability.
GTIN6911672000301

Main ingredients: Rehmannia root, Alisma rhizome, Ophiopogon root, Prepared rehmannia root, Scrophularia root, Poria, Curculigo rhizome, Magnetite, Moutan bark, Mother-of-pearl shell, Schisandra fruit, Fleeceflower vine, Prepared fleeceflower root, Floating wheat, Uncaria hook

Evidence at a Glance

Published studies directly name Gengnianan or GengNianAn. The evidence includes a small placebo-controlled study and comparator-arm studies; small samples, indirect comparisons, and incomplete reporting keep certainty limited.

Do not use if you are allergic to this product or its ingredients. Seek medical advice for severe dizziness or symptoms that do not improve after two weeks.

Uses

Common Uses

Gengnianan Tablets mainly used for menopause with symptoms hot flashes or sweating, dizziness, ringing in the ears, sleep problems, or irritability.

Traditional & Labeled Uses

滋阴清热，除烦安神

Nourishes yin, clears heat, and calms vexation or the mind

  • Menopausal symptoms, including hot flashes or sweating
  • Dizziness or tinnitus
  • Insomnia or irritability

A labeled traditional use does not establish that Gengnianan Tablets are clinically proven to treat every menopause-related symptom or replace clinician-directed care.

Understanding the TCM Perspective

Traditional Chinese Medicine terminology is not a biomedical diagnosis. It should not be used to self-diagnose menopause or to rule out another cause of sweating, dizziness, sleep disturbance, or mood change.

Gengnianan Tablets is an over-the-counter (OTC) medicine in China. This Learn information is for educational purposes only. Always consult a healthcare provider before starting TCM treatments.

Safety

Pregnancy

Product-specific pregnancy safety information was not identified in the reviewed sources. Consult a clinician or pharmacist before use during pregnancy or when trying to conceive.

Allergy

Do not use if you are allergic to Gengnianan Tablets or any listed ingredient. Stop use and seek urgent help for swelling, wheezing, trouble breathing, or another severe allergic reaction.

Breastfeeding

Product-specific breastfeeding safety information was not identified in the reviewed sources. Consult a clinician or pharmacist before use while breastfeeding.

Younger Users

The labeled use concerns menopausal symptoms. Product-specific pediatric safety and effectiveness information was not identified.

Drug Interactions

The retrieved product information does not identify specific established interaction pairs. It advises consulting a physician or pharmacist before using this product with other medicines.

When to Seek Medical Advice

Seek medical advice if dizziness is severe or symptoms have not improved after two weeks. People with menstrual irregularity or hypertension, heart disease, diabetes, kidney disease, or other illness should use the product under medical guidance.

Contraindications

  • The retrieved product information lists no specific contraindications, but states that people allergic to this product should not use it.

Evidence

Human Clinical Evidence

  • GengNianAn beverage in ovariectomized women

    Design: Randomized controlled trial

    Year: 2007

    Sample size: 69

    The abstract reports statistically significant between-group differences in the total Kupperman score, maturation index, FSH, LH, and estradiol after treatment.

    View reference ↓

  • Gengnianan Tablets as a comparator in a phase III menopause trial

    Design: Clinical trial

    Year: 2015

    Sample size: 119

    In the active-comparator trial, the Gengnianan Tablets control arm reported 38.7% total marked effectiveness after 14 days; the study did not isolate a placebo-controlled effect.

    View reference ↓

  • Gengnianan Tablets as a comparator for perimenopausal syndrome

    Design: Clinical trial

    Year: 2010

    Sample size: 80

    The Gengnianan Tablets comparator arm reported 83.8% total effectiveness after three months; limited accessible methods and the comparator design prevent attribution of an isolated treatment effect.

    View reference ↓

Verification

PRODUCT IDENTITY

Brand Name
Sanghai
Chinese Name
桑海
Manufacturer
Jiangxi Nanchang Jisheng Pharmaceutical Co., Ltd.
China drug approval number
Z20073293
Prescription status in China
Over-the-counter medicine.

These are Chinese product-registration details. They do not establish approval or availability in another country.

Verified by the AuthHerb Verification Team

  • Brand relationship confirmed
  • Manufacturer legal name confirmed
  • Approval number confirmed
  • Current packaging matched
  • Registration holder / manufacturer checked
  • Authenticity method checked
  • Label/source evidence recorded

Ingredients

This product contains the following ingredients:

Official Label Dosage

Take 6 tablets by mouth 2 to 3 times daily.

Follow the current package insert if its instructions differ.

Individual package: 0.31 g × 60 tablets

Missed Dose Information

No product-specific missed-dose instruction was identified.

Additional Directions

The retrieved product information states that the tablets are not intended for long-term use. If symptoms have not improved after two weeks, seek medical advice.

Avoid spicy foods and limit greasy foods as stated in product information. Follow the current physical package and professional advice.

A purchase option’s quantity does not define how long you should take the medicine.

Review cautions and when to seek medical advice

Frequently Asked Questions About Gengnianan Tablets

References

  1. [1]GengNianAn beverage in ovariectomized womenrandomized_controlled_trialExplore (NY) · 2007

    Population: 69 ovariectomized Chinese women.

    Indication: Menopause-related symptoms after ovariectomy

    Intervention: GengNianAn (GNA) beverage twice daily for 12 weeks (n=36).

    Comparison: Placebo beverage twice daily for 12 weeks (n=33).

    Sample size: 69

    Duration: 12 weeks

    Reported findings

    The abstract reports statistically significant between-group differences in the total Kupperman score, maturation index, FSH, LH, and estradiol after treatment.

    Interpretation

    This double-blind placebo-controlled study provides direct name-matched human evidence for GengNianAn.

    Limitations

    Small sample, ovariectomized population, and beverage administration limit generalization.

    Zhou J, Qu F, Nan R, Tang D. The effect of Chinese medicinal herbs in relieving menopausal symptoms in ovariectomized Chinese women. Explore (NY). 2007 Sep-Oct;3(5):478-484. doi:10.1016/j.explore.2007.06.002. PMID:17905357.

    Authors: Jue Zhou; Fan Qu; Rui Nan; Daiyi Tang

    Study type: randomized_controlled_trial

    PMID: 17905357

    DOI: 10.1016/j.explore.2007.06.002

  2. [2]Gengnianan Tablets as a comparator in a phase III menopause trialclinical_trial天津中医药 · 2015

    Population: Women with menopausal syndrome; accessible abstract reports 119 analysed participants in the 更年安片 control arm.

    Indication: Menopausal syndrome with liver-yin and kidney-yin deficiency

    Intervention: 更舒颗粒 intervention.

    Comparison: 更年安片 positive-control arm for 14 days.

    Sample size: 119

    Duration: 14 days

    Reported findings

    In the active-comparator trial, the Gengnianan Tablets control arm reported 38.7% total marked effectiveness after 14 days; the study did not isolate a placebo-controlled effect.

    Interpretation

    The study contributes comparator-arm human evidence that directly names Gengnianan Tablets.

    Limitations

    Gengnianan Tablets were the active comparator rather than the primary intervention, so the study does not isolate a placebo-controlled effect.

    Yan Y, Wang HJ, Wang HZ, et al. Phase III clinical study on the treatment of menopause syndrome by Gengshu particles differentiated as liver-yin and kidney-yin deficiency. Tianjin Journal of Traditional Chinese Medicine. 2015. DOI:10.11656/j.issn.1672-1519.2015.09.07.

    Full title: Phase III clinical study on treatment of menopause syndrome by Gengshu particles

    Authors: 闫颖; 王惠津; 王洪珍; 等

    Journal: 天津中医药

    Study type: clinical_trial

    DOI: 10.11656/j.issn.1672-1519.2015.09.07

  3. [3]Gengnianan Tablets as a comparator for perimenopausal syndromeclinical_trial天津中医药 · 2010

    Population: Women with perimenopausal syndrome; accessible report describes an 80-person comparator arm.

    Indication: Perimenopausal syndrome

    Intervention: Modified Liuwei Dihuang Decoction plus daidzein tablets.

    Comparison: 更年安片 comparator for a three-month course.

    Sample size: 80

    Duration: 3 months

    Reported findings

    The Gengnianan Tablets comparator arm reported 83.8% total effectiveness after three months; limited accessible methods and the comparator design prevent attribution of an isolated treatment effect.

    Interpretation

    The study adds direct-name comparator-arm evidence for Gengnianan Tablets.

    Limitations

    Comparator-arm design and limited accessible citation and method detail restrict interpretation.

    Ye LQ. Clinical observation of modified Liuwei Dihuang Decoction plus daidzein tablets for perimenopausal syndrome: 80 cases. Tianjin Journal of Traditional Chinese Medicine. 2010.

    Journal: 天津中医药

    Study type: clinical_trial

  4. [4]Clinical effect of Gengnianan Tablets in treatment of climacteric syndromeclinical_trial中国现代药物应用 · 2020

    Ge RH. Clinical effect of Gengnianan Tablets in the treatment of climacteric syndrome. China Modern Medicine Application. 2020;14(23):137–139. DOI:10.14164/j.cnki.cn11-5581/r.2020.23.061.

    Full title: Clinical effect of Gengnianan Tablets in treatment of climacteric syndrome

    Authors: 葛容辉

    Journal: 中国现代药物应用

    Study type: clinical_trial

    DOI: 10.14164/j.cnki.cn11-5581/r.2020.23.061

  5. [5]Study on the mechanism by which Guben Anshen Formula improves menopausal-syndrome model ratsanimal_study中国药房 · 2022

    Guo SS, Zhou XH, Wang SM, et al. Study on the mechanism by which Guben Anshen Formula improves menopausal-syndrome model rats. China Pharmacy. 2022;(19):2364–2368. DOI:10.6039/j.issn.1001-0408.2022.19.12.

    Authors: 郭珊珊; 周晓辉; 王淑梅; 等

    Journal: 中国药房

    Study type: animal_study

    DOI: 10.6039/j.issn.1001-0408.2022.19.12

  6. [6]Study of Wujiadan Formula on hypothalamic PLC-beta/IP3/CaM pathway in ovariectomized ratsanimal_study锦州医科大学学报 · 2023

    Zhao MY, Lü B, Li Z, et al. Study of Wujiadan Formula on the hypothalamic PLC-beta/IP3/CaM pathway in ovariectomized rats. Journal of Jinzhou Medical University. 2023;29(5):347–351. DOI:10.13210/j.cnki.jhmu.20230117.001.

    Full title: Study of Wujiadan Formula on hypothalamic PLC-beta/IP3/CaM pathway in ovariectomized rats

    Authors: 赵铭宇; 吕波; 李灼; 等

    Journal: 锦州医科大学学报

    Study type: animal_study

    DOI: 10.13210/j.cnki.jhmu.20230117.001